Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma.

Trial Profile

A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone furoate (Primary) ; Vilanterol/fluticasone furoate (Primary)
  • Indications Asthma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK
  • Most Recent Events

    • 18 May 2016 Results (post hoc analysis, n = 2019) assessing proportion of subjects achieving the minimal clinically important difference for improvement in ACQ score presented at the 112th International Conference of the American Thoracic Society.
    • 09 Jan 2012 Primary endpoint 'Time-to-exacerbation-of-symptoms' has been met, according to a GlaxoSmithKline and Theravance media release.
    • 07 Oct 2011 Actual end date (September 2011) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top